Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1129

3.

Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.

Manuvakhova M, Thottassery JV, Hays S, Qu Z, Rentz SS, Westbrook L, Kern FG.

Oncogene. 2006 Sep 28;25(44):6003-14. Epub 2006 May 8.

PMID:
16682955
4.

Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.

Guha S, Lunn JA, Santiskulvong C, Rozengurt E.

Cancer Res. 2003 May 15;63(10):2379-87.

5.

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2007;9(4):R50.

6.

MEK ablation in MCF-7 cells blocks DNA synthesis induced by serum, but not by estradiol or growth factors.

Estes NR 2nd, Thottassery JV, Westbrook L, Kern FG.

Int J Oncol. 2006 Dec;29(6):1573-80.

PMID:
17088999
7.

Constitutively active Galpha16 stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism.

Lo RK, Cheung H, Wong YH.

J Biol Chem. 2003 Dec 26;278(52):52154-65. Epub 2003 Oct 9.

8.

Inhibition of the MEK/ERK signaling pathway blocks a subset of B cell responses to antigen.

Richards JD, Davé SH, Chou CH, Mamchak AA, DeFranco AL.

J Immunol. 2001 Mar 15;166(6):3855-64.

9.

Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.

Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.

J Pharmacol Exp Ther. 2009 Jun;329(3):1063-70. doi: 10.1124/jpet.108.147306. Epub 2009 Mar 3.

10.
11.
12.

c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells.

Iijima Y, Laser M, Shiraishi H, Willey CD, Sundaravadivel B, Xu L, McDermott PJ, Kuppuswamy D.

J Biol Chem. 2002 Jun 21;277(25):23065-75. Epub 2002 Apr 8.

13.

NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells.

Furuhashi S, Sugita H, Takamori H, Horino K, Nakahara O, Okabe H, Miyake K, Tanaka H, Beppu T, Baba H.

Int J Oncol. 2012 Mar;40(3):807-15. doi: 10.3892/ijo.2011.1243. Epub 2011 Oct 24.

PMID:
22025280
14.

Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.

Wiesenauer CA, Yip-Schneider MT, Wang Y, Schmidt CM.

J Am Coll Surg. 2004 Mar;198(3):410-21.

PMID:
14992744
16.

MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.

Yip-Schneider MT, Schmidt CM.

Pancreas. 2003 Nov;27(4):337-44.

PMID:
14576498
17.

Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta.

Keshamouni VG, Mattingly RR, Reddy KB.

J Biol Chem. 2002 Jun 21;277(25):22558-65. Epub 2002 Apr 17.

18.

Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.

Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D.

Clin Cancer Res. 2007 Dec 1;13(23):7029-36.

19.

Alternate FGF2-ERK1/2 signaling pathways in retinal photoreceptor and glial cells in vitro.

Kinkl N, Sahel J, Hicks D.

J Biol Chem. 2001 Nov 23;276(47):43871-8. Epub 2001 Sep 24.

20.

Supplemental Content

Support Center